Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 19INDUSTRY 9NETWORK 7NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 2Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Doxorubicin 20Cyclophosphamide 18Radiotherapy 17Ifosfamide 13Vincristine 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Biopsy 10Etoposide 9Filgrastim 8Dactinomycin 8X-Rays 6Temozolomide 6Sirolimus 6Phantoms, Imaging 6Melphalan 6temsirolimus 5cixutumumab 5Thalidomide 5Celecoxib 5Sorafenib 4Radiation 4Nuclear Medicine Department, Hospital 4Ipilimumab 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Carboplatin 4pazopanib 3ixabepilone 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Sarcoma × Trabectedin × Clear all
NCT01453283 2017-07-02

Tabectedin to Treat Children and Adolescents With Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
12 enrolled
CNSGastrointestinalGenitourinarySarcoma

Brain Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT00017030 2013-06-26

Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡